格列美脲对2型糖尿病患者代谢水平及血清IL-1β的影响  

Effects of Glycolipide on Metabolic Levels and IL-1β in Patients with Type 2 Diabetes Mellitus

作　　者：李凤[1] 翟晨辉[1] 侯志梅[1] 

机构地区：[1]新疆医科大学第二附属医院老年病科,乌鲁木齐830028

出　　处：《医学综述》2018年第1期184-188,共5页Medical Recapitulate

基　　金：新疆医科大学科研创新基金(XYDCX201520)

摘　　要：目的探讨格列美脲对新诊断2型糖尿病(T2DM)患者代谢水平及血清白细胞介素(IL)-1β的变化。方法将2014年1月至2016年12月来新疆医科大学第二附属医院就诊的84例新诊断T2DM患者依据随机数字法分为格列美脲联合甘精胰岛素(GI)组和诺和锐30(AS30)组,各42例。GI组给予甘精胰岛素睡前皮下注射,并口服格列美脲治疗3个月;AS30组予以诺和锐30于早晚餐时皮下注射3个月。对比两组治疗前后空腹血糖(FPG)、餐后2 h血糖(2hPBG)、糖化血红蛋白(HbA_(1c))、体质指数(BMI)、三酰甘油(TG)、总胆固醇(TC)及血清IL-1β的变化。结果治疗后,GI组FPG、2hPBG、HbA_(1c)低于AS 30组[(6.72±1.01)mmol/L比(8.14±1.30)mmol/L、(7.21±1.10)mmol/L比(8.70±1.33)mmol/L、(7.05±0.82)%比(8.02±1.15)%](P<0.01);治疗后,GI组BMI、TG、TC低于AS30组[(22.75±2.59)kg/m^2比(21.35±2.62)kg/m^2、(4.58±1.06)mmol/L比(4.29±1.21)mmol/L、(2.17±1.01)mmol/L比(2.22±0.93)mmol/L](P<0.01);治疗后,GI组IL-1β低于AS 30组[(4.42±2.32)ng/L比(8.62±3.67)ng/L](P<0.01)。结论格列美脲可显著降低T2DM患者血糖,改善脂代谢,降低血清IL-1β水平,降低炎症反应,从而抑制NALP3炎性体的活性。Objective To explore the changes of the metabolic markers and the serum interleukin（IL）-1 β in the new diagnosis of type 2 diabetes mellitus（T2DM）. Methods A total of 84 patients with newly diagnosed T2DM admitted to the Second Affiliated Hospital of Xinjiang Medical University between Jan. 2014 and Dec. 2014 were divided into a glycolipide joint insulin（GI） group and an aspart 30 （AS30） group according to the random number method, 42 cases each. The GI group was given an insulin glargine injection before bed and oral glycolipide, for 3 months. The AS30 group was given a 3-month hypodermic injection of AS30 during breakfast and evening meal. The fasting plasma glucose （FPG） , 2 hours of postprandial blood glucose （ PBG ） , glycosylated hemoglobin （ HbA1c ） , body mass index （ BMI ） , triglycerides （TG） , total cholesterol（TC） and serum IL-1β changes of the two groups before and after treatment were compared. Results After treatment,FPG,2 h PBG,HBAxc of the IG group were lower than those of the AS30 group[ （6.72 ± 1.01 ） mmol/L vs （8.14 ± 1.30） mmol/L,（7.21 ±1.10） mmol/L vs （8.70±1.33） mmol/L,（7.05±0.82）% vs （8.02 ±1.15）%] （P〈 0.01 ）. After treatment, BMI,TC,TG of the IG group were lower than those of the AS30 group [ （22.75 ± 2.59） kg/m2 vs （21.35 ±2.62） kg/m2, （4.58 ± 1.06） mmol/L vs （4.29 ± 1.21 ） retool/L, （2. 17 ± 1.01 ） mmoL/L vs （2.22 ± 0.93） mmol/L] （ P 〈 0.01 ）. After treatment, IL-1 β of the IG group was lower than that of the AS30 group [ （4.42 ± 2.32） ng/L vs （ 8.62 ± 3.67） ng/L ] （ P 〈 0.01 ）. Conclusion Glycolipide can significantly reduce blood glucose in T2DM patients, improve lipid metabolism, decrease the serum IL-1β level, and reduce the inflammatory response, thus inhibiti the activity of NALP3 inflammasome.

关 键 词：2型糖尿病 格列美脲 白细胞介素1Β NALP3炎性体 

分 类 号：R453.9[医药卫生—治疗学]